---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-25-000069"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T17:19:58.886324+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus refinances with $250M credit facility, cuts interest cost by 350 bps

## Summary
- New $250M senior secured term loan replaces existing $125M facility; $150M drawn at closing, $100M incremental capacity available in two $50M tranches through Dec 31, 2026.
- Interest rate reduced by 350 bps to SOFR + 5.00% (floor 3.50%); quarterly interest payments, bullet maturity at 5 years.
- Converted from amortizing to bullet maturity; significantly reduced prepayment fees; no additional performance conditions or financial covenants for incremental tranches.
- Evolus no longer required to make principal payments in 2026; refinancing enhances cash generation and financial flexibility.
- Funds managed by Pharmakon Advisors, LP; Leerink Partners served as exclusive financial advisor.

## SEC filing metadata
- accession: 0001570562-25-000069
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/0001570562-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/eols-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-25-000069
- JSON: https://secwatch.observer/filing/0001570562-25-000069.json
- Plain text: https://secwatch.observer/filing/0001570562-25-000069.txt

## Key facts
- Debt Financings
  Evolus, Inc. incurred term loan of up to $250,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP at 3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t maturing 5th year anniversary of the Tranche A Closing Date.
  - Instrument: term loan
  - Principal: up to $250,000,000
  - Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP
  - Rate: 3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t
  - Maturity: 5th year anniversary of the Tranche A Closing Date
  - Event: incurrence
  source text: the Lenders agreed to make term loans to the Company in an aggregate principal amount of up to $250,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/0001570562-25-000069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.